A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Langdon Miller, MD
AI Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Clearview Cancer Institute
Huntsville, Alabama, United States
- Mayo Clinic
Jacksonville, Florida, United States
- Winship Cancer Institute at Emory University
Atlanta, Georgia, United States
- Horizon Oncology Research, Inc.
Lafayette, Indiana, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Mayo Clinic
Rochester, Minnesota, United States
- New York University School of Medicine
New York, New York, United States
- Weill Cornell Medical College
New York, New York, United States
- University of Texas Md Anderson Cancer Center
Houston, Texas, United States
- Virginia Cancer Specialists
Fairfax, Virginia, United States
- Virginia Mason Medical Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2015
- Primary completion
- 9 Mar 2020
- Completion
- 30 Mar 2023
- Last update posted
- 22 Aug 2024
- Registered enrollment
- 62
- Registry id
- NCT02594384
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.